AMOEBA (EPA:ALMIB) - AMOEBA SIGNS A NON-EXCLUSIVE DEVELOPMENT AND MARKETING AGREEMENT IN SWITZERLAND WITH STÄHLER FOR ITS VINE BIOCONTROL PRODUCT

Transparency directive : regulatory news

18/12/2020 08:30

PRESS RELEASE

AMOEBA SIGNS A NON-EXCLUSIVE DEVELOPMENT AND MARKETING AGREEMENT IN SWITZERLAND
              WITH STÄHLER FOR ITS VINE BIOCONTROL PRODUCT

Chassieu (France), December 18, 2020 - 8.30 am- AMOEBA (FR0011051598 - ALMIB),
producer of a biological biocide capable of eliminating the risk in water and
human wounds, and of a biocontrol product for plant protection, still in the
testing phase, announces the signature of a Term Sheet with STÄHLER SUISSE SA,
for the development and marketing of its biocontrol product against vine downy
mildew in Switzerland.

This signature, with a highly recognized local player in the crop protection
market, follows on from the partnership announced in March 2020 to evaluate the
performance of the biocontrol fungicide containing AMOEBA's active substance:
the amoeba lysate Willaertia magna C2c Maky.

The aim of the Term Sheet is to define the terms of the collaboration between
the two companies before and after the marketing of the product on the Swiss
territory with a view to signing a commercial partnership contract within 12
months.

Amoéba will carry out the regulatory tests necessary for the registration of
its product and STÄHLER will define, through additional field trials, the
marketing and commercial positioning of the product.

Amoéba has made a non-exclusive commitment with STÄHLER concerning the vine
application over a marketing period of several years in Switzerland, where vine
downy mildew is an important market and the search for sustainable treatment
solutions a strong objective for all Swiss agriculture.

"Vine downy mildew is one of the main diseases in the Swiss vineyard. Its
control today requires repeated applications of phytosanitary products.
AMOEBA's biocontrol product was tested for the first time by Stähler Suisse SA
in 2020 in 2 trials. The results were very encouraging and it has been decided
to continue the testing and development work. The product could become an
important tool for the move towards a more ecological viticulture", explains
Simon Gasser, Head of Development and Certification at STÄHLER SUISSE SA.

"As the Swiss vineyard offers a wide variety of grape varieties, the choice of
STÄHLER as a partner was a natural one. As a leading player in its domestic
market, specialising in particular in crops such as vines, arboriculture and
market gardening, the company is already heavily involved in the development
and marketing of biocontrol solutions. Our common goal is to provide local
winegrowers with an effective solution for vine protection without impacting
the environment "comments Fabrice PLASSON, Chairman and CEO of Amoéba.

About STÄHLER SUISSE SA

STÄHLER SUISSE SA is one of the leading distributors of crop protection
products and biocontrol solutions in Switzerland, with a strong specialization
on grapes and other valuable fruit and vegetables as well as all field crops.
The mission of STÄHLER SUISSE SA covers the development, registration and
marketing of plant protection products for professional and non-professional
markets. STÄHLER SUISSE SA is an independent Swiss company which equity is
held by its management, thus guaranteeing the implementation of a long-term
strategy for the business conduct.

Contacts:
Stähler Suisse SA
Simon Gasser
Responsable Développement et régistration
41 (0)62 746 80 05
simon.gasser@staehler.ch

About AMOEBA:
Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.
Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on Euronext Growth. The Company is
a member of the BPIfrance Excellence network and is eligible for the PEA-PME
SME equity savings plan setup. More information on www.amoeba-biocide.com.

(1): Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2): Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
     MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies,"
     Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
Directeur Général Adjoint
+33 4 26 69 16 00
v.filiatre@amoeba-nature.com

Calyptus
Relations investisseurs & Presse
Grégory BOSSON / Mathieu CALLEUX
+33 1 53 65 37 90 /91
amoeba@calyptus.net

Disclaimer
This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the Universal
Registration Document of AMOEBA filed with the French Financial Markets
Authority (Autorité des Marchés Financiers) on April 30, 2020 under number
D20-0416 (a copy of which is available on www.amoeba-biocide.com). The
forward-looking statements contained in this press release are also subject to
risks not yet known to AMOEBA or not currently considered material by

AMOEBA. The occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of AMOEBA to be materially
different from such forward-looking statements.

Adresse : 38 Avenue des Frères Montgolfier, 69680 CHASSIEU
Société Anonyme au capital de 311 578,38 EUR
RCS Lyon 523 877 215

Tel: +33 (0)4 26 69 16 00 ? Email: contact@amoeba-nature.com
Linkedin: @amoeba-nature ? Twitter: @AmoebaNature
www.amoeba-nature.com

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - AMOEBA SIGNS A NON-EXCLUSIVE DEVELOPMENT AND MARKETING AGREEMENT IN SWITZERLAND WITH STÄHLER FOR ITS VINE BIOCONTROL PRODUCT

Transparency directive : regulatory news

AMOEBA's latest news

Other stories